"instanceType","rationale","uuid:ID","id","versionIdentifier"
"StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","8d135b76-a5d9-43db-87f3-fcb573b9eeec","StudyVersion_1","2"
